-

Agilent Announces Cash Dividend of 25.5 Cents per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on July 22, 2026, to all shareholders of record as of the close of business on June 30, 2026.

The timing and amounts of future dividends are subject to the determination and approval of Agilent’s board of directors.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the company’s dividend program and future payment obligations. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties are detailed in Agilent’s filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended Jan. 31, 2026. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

Contacts

INVESTOR CONTACT:
Tejas Savant
+1 917-574-4018
tejas.savant@agilent.com

MEDIA CONTACT:
Kate Coyle
+1 302-633-7490
kate.coyle@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions
$Cashtags

Contacts

INVESTOR CONTACT:
Tejas Savant
+1 917-574-4018
tejas.savant@agilent.com

MEDIA CONTACT:
Kate Coyle
+1 302-633-7490
kate.coyle@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the NovoStation Sample Preparation System, a new automated platform designed to help laboratories simplify and streamline flow cytometry sample preparation. When paired with a NovoCyte flow cytometer and NovoExpress software, NovoStation offers an integration-ready solution that enables a hands-free sample-to-answer workflow, helping scientists spend less time preparing samples and more time...

Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent BioTek Gen5 AI cell identification module, a new image analysis software add-on that incorporates AI-based cell identification and segmentation into BioTek Gen5 imaging analysis. Developed for use with compatible Agilent BioTek automated imaging systems, the module uses AI-based segmentation without requiring conventional threshold setting or parameter tuning. By incorporating the...

Agilent Launches TapeStationDx Systems for Clinical NGS Sample Quality Control

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent 4150 TapeStationDx system, Agilent 4200 TapeStationDx system and Agilent TapeStationDx software, extending the company's automated electrophoresis portfolio into regulated clinical laboratory environments. The new CE-IVD-labeled systems and software are designed to support standardized and traceable quality control of DNA and RNA samples used in clinical next-generation sequencing...
Back to Newsroom